1-Oxo-2-methyl-1,2-dihydro-naphthalin

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-Oxo-2-methyl-1,2-dihydro-naphthalin
• 英文别名: 1(2H)-Naphthalenone, 2-methyl；2-methyl-2H-naphthalen-1-one
• 化学式: C₁₁H₁₀O
• 分子量: 158.2
• InChiKey: OVRFMMLOGHJZLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  甲醇 、 萘酚 在 aluminum oxide 作用下， 生成 1-Oxo-2-methyl-1,2-dihydro-naphthalin
  参考文献：
  名称：

  Alumina-catalyzed rreactions of hydroxyarenes and hydroaromatic ketones. I. Reactions of 1-naphthol with methanol

  摘要：

  DOI：

  10.1021/jo01268a036

文献信息

• [EN] N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] DÉRIVÉS DE N-ACYLHYDRAZONE UTILES COMME MODULATEURS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
  申请人：NEUROSEARCH AS

  公开号：WO2009065854A1

  公开（公告）日：2009-05-28

  This invention relates to N-acylhydrazone derivatives (I), which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  这项发明涉及N-酰基腙衍生物（I），发现它们可用作尼古丁型乙酰胆碱受体的调节剂。由于其药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或紊乱、内分泌疾病或紊乱、神经退行性疾病或紊乱、炎症、疼痛以及化学物质滥用终止引起的戒断症状等多种疾病或紊乱具有用处。
• [EN] N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] DÉRIVÉS DE N-ACYLHYDRAZONE UTILES EN TANT QUE MODULATEURS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
  申请人：NEUROSEARCH AS

  公开号：WO2009065850A1

  公开（公告）日：2009-05-28

  This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及N-酰基腙衍生物，这些衍生物被发现有用作为尼古丁乙酰胆碱受体调节剂。由于它们的药理特性，该发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或疾病、内分泌疾病或疾病、神经退行性疾病或疾病、炎症、疼痛以及由化学物质滥用终止引起的戒断症状等多种疾病或疾病可能有用。
• INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES
  申请人：Quibell Martin

  公开号：US20090247471A1

  公开（公告）日：2009-10-01

  Compounds of general formula (I) or general formula (II):— wherein R 1 , P 1 , P 2 , Q, Y, (X) o , (W) n , (V) m , Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds.

  通式(I)或通式(II)的化合物：其中R1、P1、P2、Q、Y、(X)o、(W)n、(V)m、Z和U的定义如规范中所述，是cruzipain和其他半胱氨酸蛋白酶抑制剂，可用作治疗剂，例如在查加斯病中，或用于验证治疗靶点化合物。
• DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS
  申请人：Odermatt Alex

  公开号：US20090062401A1

  公开（公告）日：2009-03-05

  The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes.

  本发明涉及具有十二环骨架的化合物，这些化合物的药学上可接受的盐以及含有这些化合物之一的药物组合物，该组合物还包含药学上可接受的载体、赋形剂和/或稀释剂。所述的十二环衍生化合物可用于预防和/或治疗糖尿病I型、糖尿病II型、结核病和其他传染病、增殖性疾病、癌症、神经退行性疾病、肥胖症、认知功能障碍和代谢综合征。
• N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：Nardi Antonio

  公开号：US20100280092A1

  公开（公告）日：2010-11-04

  This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及N-酰基腙衍生物，其被发现可作为尼古丁乙酰胆碱受体的调节剂。由于它们的药理特性，本发明的化合物可能对与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统有关的疾病或障碍，平滑肌收缩相关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，炎症、疼痛以及由于滥用化学物质而导致的戒断症状的治疗可能有用。